Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Update

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 137,100 shares, a growth of 13.0% from the February 29th total of 121,300 shares. Currently, 2.4% of the shares of the stock are short sold. Based on an average daily volume of 45,400 shares, the short-interest ratio is currently 3.0 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Greenwich LifeSciences in a research report on Wednesday, February 28th.

Insider Transactions at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 2,500 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were purchased at an average cost of $19.98 per share, for a total transaction of $49,950.00. Following the completion of the transaction, the chief executive officer now owns 5,347,777 shares of the company’s stock, valued at approximately $106,848,584.46. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased 20,800 shares of company stock valued at $270,482 over the last 90 days. Corporate insiders own 52.86% of the company’s stock.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of institutional investors have recently modified their holdings of GLSI. Vanguard Group Inc. grew its holdings in Greenwich LifeSciences by 150.2% in the first quarter. Vanguard Group Inc. now owns 375,200 shares of the company’s stock valued at $7,362,000 after purchasing an additional 225,213 shares during the period. State Street Corp grew its holdings in Greenwich LifeSciences by 1.8% in the first quarter. State Street Corp now owns 66,485 shares of the company’s stock valued at $1,304,000 after purchasing an additional 1,176 shares during the period. Bank of America Corp DE grew its holdings in Greenwich LifeSciences by 100.2% in the first quarter. Bank of America Corp DE now owns 6,213 shares of the company’s stock valued at $122,000 after purchasing an additional 3,110 shares during the period. Renaissance Technologies LLC purchased a new stake in Greenwich LifeSciences in the second quarter valued at approximately $891,000. Finally, Millennium Management LLC purchased a new stake in Greenwich LifeSciences in the second quarter valued at approximately $765,000. Institutional investors and hedge funds own 4.16% of the company’s stock.

Greenwich LifeSciences Stock Performance

GLSI stock opened at $17.49 on Wednesday. Greenwich LifeSciences has a one year low of $7.58 and a one year high of $21.44. The stock has a market capitalization of $224.75 million, a PE ratio of -24.63 and a beta of 1.37. The company has a fifty day moving average of $13.52 and a 200-day moving average of $11.14.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.